Human breast cancer biopsies of patients treated or not with the combination of palbociclib and fulvestrant

ABSTRACT: Metastatic HR+ HER2- breast cancer is an intractable disease that resists to the first-line treatment based on the combination of CDK4/6 inhibitor and hormone therapy (HT). To identify targets that further increase palbociclib-HT efficacy, we utilized biopsies from cancer patients who showed recurrence after treatment, HR+HER2- luminal cancer cells sensitive and resistant to the palbociclib-HT. Proteomic analysis of human samples revealed an upregulation of the oxidative stress-triggered proteasome subunit alpha7 (PSMA7) in metastatic relapses in different organs after patient's resistance to palbociclib-HT combination.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Breast Cancer Cell

DISEASE(S): Breast Cancer

SUBMITTER: Dominique Baiwir  

LAB HEAD: Nor Eddine Sounni

PROVIDER: PXD053296 | Pride | 2025-05-07

REPOSITORIES: Pride